Brief: Arch Therapeutics says AC5 topical hemostatic device stopped bleeding in patients in clinical study
31/10/2016 11:57
Oct 31 (Reuters) - Arch Therapeutics Inc ARTH.PK
* Arch Therapeutics reports AC5 topical hemostatic device
successfully stopped bleeding in patients on antiplatelet
therapy in recently completed clinical study
Source text for Eikon: urn:newsml:reuters.com:*:nMKWTLPyga
Further company coverage: ARTH.PK
((bangalore.newsroom@thomsonreuters.com;))
Recent news on Arch Therapeutics
See all newsBrief: Arch Therapeutics Announces Intent To Uplist From OTC To National Exchange
Brief: Arch Therapeutics Raises Approximately $3.5 Million In Convertible Note Financing
Brief: Arch Raises About $1.1 Mln With Convertible Note Issuance
Brief: Arch Therapeutics Receives Marketing Clearance From The US FDA Related To The AC5 Topical Gel Supply Chain
Brief: Arch Therapeutics Withdraws 510(K) With Plans To Resubmit After Further Discussions With FDA